HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION safely and effectively. See full prescribing information for MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION. MAGNESIUM SULFATE IN DEXTROSE injection, for intravenous use Initial U.S. Approval: 1941 INDICATIONS AND USAGEDOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSSupplied in premixed single-dose flexible plastic containers: (3)
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions are flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central nervous system (CNS) depression proceeding to respiratory paralysis and hypocalcemia. Bradycardia, pulmonary edema, decreased respiratory rate, lethargy, sedation, somnolence, visual disturbances, and hypermagnesemia are also reported (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc., at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONSPatients with severe renal impairment and/or a urine output less than 100 mL every 4 hours are at greater risk for increased magnesium concentrations that may lead to toxicity (8.6) See 17 for PATIENT COUNSELING INFORMATION. Revised: 7/2022 |
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION safely and effectively. See full prescribing information for MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION. MAGNESIUM SULFATE IN DEXTROSE injection, for intravenous use Initial U.S. Approval: 1941 INDICATIONS AND USAGEDOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSSupplied in premixed single-dose flexible plastic containers: (3)
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions are flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central nervous system (CNS) depression proceeding to respiratory paralysis and hypocalcemia. Bradycardia, pulmonary edema, decreased respiratory rate, lethargy, sedation, somnolence, visual disturbances, and hypermagnesemia are also reported (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc., at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONSPatients with severe renal impairment and/or a urine output less than 100 mL every 4 hours are at greater risk for increased magnesium concentrations that may lead to toxicity (8.6) See 17 for PATIENT COUNSELING INFORMATION. Revised: 7/2022 |
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION safely and effectively. See full prescribing information for MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION. MAGNESIUM SULFATE IN DEXTROSE injection, for intravenous use Initial U.S. Approval: 1941 INDICATIONS AND USAGEDOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSSupplied in premixed single-dose flexible plastic containers: (3)
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions are flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central nervous system (CNS) depression proceeding to respiratory paralysis and hypocalcemia. Bradycardia, pulmonary edema, decreased respiratory rate, lethargy, sedation, somnolence, visual disturbances, and hypermagnesemia are also reported (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc., at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONSPatients with severe renal impairment and/or a urine output less than 100 mL every 4 hours are at greater risk for increased magnesium concentrations that may lead to toxicity (8.6) See 17 for PATIENT COUNSELING INFORMATION. Revised: 7/2022 |
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.